Adverse drug events and the associated factors in patients with chronic Chagas disease

Lopes, Luiza Braz da Cunha; Pereira, Raquel Rodrigues; Andrade, Patricia Mello; Carneiro, Fernanda Martins; Mediano, Mauro Felippe Felix; Kilgore, Sophia Isabel Linnemann; Hasslocher‐Moreno, Alejandro Marcel; Sousa, Andréa Silvestre de; Oliveira, Manoel Marques Evangelista; Saraiva, Roberto Magalhães; Holanda, Marcelo Teixeira de; Silva, Gilberto Marcelo Sperandio da

doi:10.1590/0037-8682-0443-2019

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering that as high as 30% to 40% of patients with CD will develop cardiac or digestive symptoms that chronically require medical assistance and pharmacological treatment[ 9 ], pharmaceutical care emerges as an important auxiliary strategy to improve medication compliance, minimize adverse drug events, and improve quality of life[ 103 ]. Therefore, pharmaceutical care is an important strategy that should be implemented in the follow-up of patients with CHD and HF, as it could help to identify adverse drug events and suggest alternatives to minimize these side effects[ 104 ].…”

Section: Non-pharmacological Strategiesmentioning

confidence: 99%

Chagas heart disease: An overview of diagnosis, manifestations, treatment, and care

Saraiva¹,

Mediano²,

Mendes³

et al. 2021

WJC

View full text Add to dashboard Cite

Chagas heart disease (CHD) affects approximately 30% of patients chronically infected with the protozoa Trypanosoma cruzi . CHD is classified into four stages of increasing severity according to electrocardiographic, echocardiographic, and clinical criteria. CHD presents with a myriad of clinical manifestations, but its main complications are sudden cardiac death, heart failure, and stroke. Importantly, CHD has a higher incidence of sudden cardiac death and stroke than most other cardiopathies, and patients with CHD complicated by heart failure have a higher mortality than patients with heart failure caused by other etiologies. Among patients with CHD, approximately 90% of deaths can be attributed to complications of Chagas disease. Sudden cardiac death is the most common cause of death (55%–60%), followed by heart failure (25%–30%) and stroke (10%–15%). The high morbimortality and the unique characteristics of CHD demand an individualized approach according to the stage of the disease and associated complications the patient presents with. Therefore, the management of CHD is challenging, and in this review, we present the most updated available data to help clinicians and cardiologists in the care of these patients. We describe the clinical manifestations, diagnosis and classification criteria, risk stratification, and approach to the different clinical aspects of CHD using diagnostic tools and pharmacological and non-pharmacological treatments.

show abstract

Section: Non-pharmacological Strategiesmentioning

confidence: 99%